KGM-100

Hazard statements (CLP)

H319

Code

Statements

H319

Causes serious eye irritation

2.1 Classification of the substance or mixture

m-Tolylidene diisocyanate 26471-62-5 247-722-4 0.1-1% Xn: R20-R42 Xylene 1330-20-7 215-535-7 1-10% F R10, Xn R20/21

Hazard statements

Xn: Harmful R10: Flammable (Category 1), R20/21: Harmful by inhalation and in contact with skin- serious eye damage/irritation (Category 2) (H319) R42: May cause sensitisation by inhalation - respiratory system (Category 1) SECTION 3. HEALTH HAZARD INFORMATION Potential Health Effects: Primary Routes of exposure: Routes of entry for solids and liquids include eye and skin contact, ingestion and inhalation. Routes of entry for gases include inhalation and eye contact. Skin contact may be route of entry for liquefied gases. Human Effects and Symptoms of Overexposure: Skin Contact: Some components used in this material are reported to cause severe irritation and will probably irritate human skin. Skin sensitisation and irritation may develop after repeated and/or prolonged contact with human skin. Eye Contact: Some components used in this material are reported to induce chemical burns in rabbit eye studies; a similar degree of eye injury may develop after contact with human eyes. Skin absorption: Systemically toxic concentrations of this product will probably not be absorbed through human skin. Ingestion: Irritation of chemical burns of the mouth, pharynx, oseophagus and stomach can develop following ingestion. SECTION 3. HEALTH HAZARD INFORMATION CONT’D Inhalation: Vapours can irritate eyes, nose and respiratory passages and may cause drowsiness & dizziness. Severe overexposure may induce respiratory sensitisation with asthma-like symptoms. Symptoms include chronic cough, tightness of chest with difficulty breathing. These symptoms may be immediate or delayed up to several hours after exposure. There are reports that chronic exposures may result in permanent decreases in lung function. ACUTE - Exposure may cause mucous membrane and respiratory tract irritation, tightness of chest, headache, shortness of breath and a dry cough. At concentrations exceeding current occupational limits and for sensitised individuals at levels less than or greater than current occupational limits, asthma-like symptoms may occur. These symptoms may include coughing, wheezing and shortness of breath. Hypersensitive pneumonias may also occur if the person is sensitised. This syndrome is characterised by fever, non-productive cough, wheezing, chills and shortness of breath. The effects of acute exposure may be delayed in onset up to 12-24 hours. CHRONIC - Repeated exposure above current occupational limits may cause an allergic sensitisation of the respiratory tract. This is characterised by an asthma-like response upon exposure to the chemical. The symptoms may include coughing, wheezing, shortness of breath and chest tightness, and may be fatal. Medical Conditions Generally Aggravated By Exposure: Cardiovascular disease, Asthma or Asthmatic Bronchitis, allergic disease, chronic respiratory disease, sinusitis, headache, dizziness.